Jingjing Yang
NO. 28 Fuxing Road
Haidian, 100853, China
Haidian, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Therapeutic-drug-monitoring-based ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: a randomized, multicenter, phase 3 clinical trial.
Journal: Cancer letters
Published: March 28, 2026
Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia.
Journal: Clinical and experimental medicine
Published: January 06, 2026
Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis.
Journal: Frontiers in immunology
Published: September 04, 2025
Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).
Journal: Cancer pathogenesis and therapy
Published: April 21, 2025
METTL3-mediated m6A modification promotes FOXO3 expression and anthracycline resistance in acute myeloid leukemia cells through autophagy regulation
Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Published: March 31, 2025
A pragmatic monitoring model for risk of non-relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem-cell transplantation.
Journal: British journal of haematology
Published: February 12, 2025
A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Journal: International immunopharmacology
Published: December 13, 2024
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.
Journal: Frontiers in immunology
Published: November 08, 2024
Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: May 22, 2024
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies.
Journal: Annals of transplantation
Published: October 11, 2022
Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins.
Journal: Antiviral research
Published: January 16, 2022
Last Updated: 09/26/2026